New insights from the structure-function analysis of the catalytic region of human platelet phosphodiesterase 3A - A role for the unique 44-amino acid insert

被引:11
作者
Hung, Su-Hwi
Zhang, Wei
Pixley, Robin A.
Jameson, Bradford A.
Huang, Yu Chu
Colman, Roberta F.
Colman, Robert W.
机构
[1] Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA
[2] Drexel Univ, Coll Med, Dept Biochem, Philadelphia, PA 19104 USA
[3] Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA
关键词
CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; INHIBITED CAMP-PHOSPHODIESTERASE; SUBTILIS ADENYLOSUCCINATE LYASE; SITE-DIRECTED MUTAGENESIS; SERPIN-PROTEASE COMPLEX; CRYSTAL-STRUCTURE; 8-<(4-BROMO-2,3-DIOXOBUTYL)THIO>ADENOSINE 3',5'-CYCLIC-MONOPHOSPHATE; ACTIVE-SITE; INACTIVATION; EXPRESSION;
D O I
10.1074/jbc.M606558200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human phosphodiesterase 3A (PDE3A) degrades cAMP, the major inhibitor of platelet function, thus potentiating platelet function. Of the 11 human PDEs, only PDE3A and 3B have 44-amino acid inserts in the catalytic domain. Their function is not clear. Incubating Sp-adenosine-3', 5'-cyclic-S-(4-bromo-2,3-dioxobutyl) monophosphorothioate (Sp-cAMPS-BDB) with PDE3A irreversibly inactivates the enzyme. High pressure liquid chromatography ( HPLC) analysis of a tryptic digest yielded an octapeptide within the insert of PDE3A ((K)(TYNVTDDK813)-Y-806), suggesting that a substrate-binding site exists within the insert. Because Sp-cAMPS-BDB reacts with nucleophilic residues, mutants Y807A, D811A, and D812A were produced. Sp-cAMPS-BDB inactivates D811A and D812A but not Y807A. A docking model showed that Tyr(807) is 3.3 angstroms from the reactive carbon, whereas Asp(811) and Asp(812) are > 15 angstroms away from Sp-cAMPS-BDB. Y807A has an altered K-m but no change in k(cat). Activity of wild type but not Y807A is inhibited by an anti-insert antibody. These data suggest that Tyr(807) is modified by Sp-cAMPS-BDB and involved in substrate binding. Because the homologous amino acid in PDE3B is Cys(792), we prepared the mutant Y807C and found that its K-m and k(cat) were similar to the wild type. Moreover, Sp-cAMPS-BDB irreversibly inactivates Y807C with similar kinetics to wild type, suggesting that the tyrosine may, like the cysteine, serve as a H donor. Kinetic analyses of nine additional insert mutants reveal that H782A, T810A, Y814A, and C816S exhibit an altered k(cat) but not K-m, indicating that catalysis is modulated. We document a new functional role for the insert in which substrate binding may produce a conformational change. This change would allow the substrate to bind to Tyr(807) and other amino acids in the insert to interact with residues important for catalysis in the active site cleft.
引用
收藏
页码:29236 / 29244
页数:9
相关论文
共 32 条
  • [1] CRYSTAL-STRUCTURES OF NATIVE AND INHIBITED FORMS OF HUMAN CATHEPSIN-D - IMPLICATIONS FOR LYSOSOMAL TARGETING AND DRUG DESIGN
    BALDWIN, ET
    BHAT, TN
    GULNIK, S
    HOSUR, MV
    SOWDER, RC
    CACHAU, RE
    COLLINS, J
    SILVA, AM
    ERICKSON, JW
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (14) : 6796 - 6800
  • [2] A new pharmacological treatment for intermittent claudication:: Results of a randomized, multicenter trial
    Beebe, HG
    Dawson, DL
    Cutler, BS
    Herd, JA
    Strandness, DE
    Bortey, EB
    Forbes, WP
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (17) : 2041 - 2050
  • [3] 3-DIMENSIONAL STRUCTURE OF THE COMPLEX OF THE RHIZOPUS-CHINENSIS CARBOXYL PROTEINASE AND PEPSTATIN AT 2.5-A RESOLUTION
    BOTT, R
    SUBRAMANIAN, E
    DAVIES, DR
    [J]. BIOCHEMISTRY, 1982, 21 (26) : 6956 - 6962
  • [4] Partial characterization of the active site human platelet cAMP phosphodiesterase, PDE3A, by site-directed mutagenesis
    Cheung, PP
    Yu, L
    Zhang, H
    Colman, RW
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1998, 360 (01) : 99 - 104
  • [5] Human platelet cGI-PDE: Expression in yeast and localization of the catalytic domain by deletion mutagenesis
    Cheung, PP
    Xu, H
    McLaughlin, MM
    Ghazaleh, FA
    Livi, GP
    Colman, RW
    [J]. BLOOD, 1996, 88 (04) : 1321 - 1329
  • [6] 3 NEW POTENTIAL CAMP AFFINITY LABELS - INACTIVATION OF HUMAN-PLATELET LOW KM CAMP PHOSPHODIESTERASE BY 8-[(4-BROMO-2,3-DIOXOBUTYL)THIO]ADENOSINE 3',5'-CYCLIC-MONOPHOSPHATE
    GRANT, PG
    DECAMP, DL
    BAILEY, JM
    COLMAN, RW
    COLMAN, RF
    [J]. BIOCHEMISTRY, 1990, 29 (04) : 887 - 894
  • [7] PURIFICATION AND CHARACTERIZATION OF A HUMAN-PLATELET CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE
    GRANT, PG
    COLMAN, RW
    [J]. BIOCHEMISTRY, 1984, 23 (08) : 1801 - 1807
  • [8] A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease
    Gum, PA
    Kottke-Marchant, K
    Welsh, PA
    White, J
    Topol, EJ
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (06) : 961 - 965
  • [9] Crystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 3-isobutyl-1-methylxanthine binding
    Huai, Q
    Wang, HC
    Zhang, W
    Colman, RW
    Robinson, H
    Ke, HM
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (26) : 9624 - 9629
  • [10] Crystal structures of phosphodiesterases 4 and 5 in complex with inhibitor 3-isobutyl-1-methylxanthine suggest a conformation determinant of inhibitor selectivity
    Huai, Q
    Liu, YD
    Francis, SH
    Corbin, JD
    Ke, HM
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (13) : 13095 - 13101